Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Tumor Lysis Syndrome 1Lymphoma 1Leukemia 1Inflammation 1Hyperuricemia 1Gout 1Cardiovascular Diseases 1Arthritis 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Febuxostat × Clear all
NCT02500641 2019-06-21

FORWARD

Menarini International Operations Luxembourg SA

Phase 4 Completed
196 enrolled 9 charts

Arthritis, Cardiovascular Diseases, Gout, Inflammation, Hyperuricemia

NCT01724528 2014-11-03

FLORENCE

Menarini Group

Phase 3 Completed
346 enrolled 16 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡